Lymphoepithelial carcinoma of the parotid gland: Clinicopathological analysis of 146 cases from a single institute.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35915861.
- Also identified by DOI 10.1002/hed.27083.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Parotid lymphoepithelial carcinoma (LEC) is a rare malignant tumor. The purpose of this study was to investigate the clinicopathological features of parotid LEC. All patients clinicopathological information diagnosed parotid LEC from 2005 to 2017 were analyzed. A total of 146 cases of parotid LECs were identified. Of these, 126 (86.3%) were primary and 20 (13.7%) were secondary LECs. Patients with secondary LEC tended to have tumors with earlier TNM staging than those with primary (p = 0.031). The tumor cells in 87 (94.6%, 87/92) cases tested positive for Epstein-Barr virus (EBV). Cervical node metastases were present at diagnosis in 46 (31.5%) cases. Overall survival at 5 and 10 years was 97.0% and 90.8%, respectively. Older age was an adverse prognostic indicator for overall survival (p < 0.001). Parotid LEC is associated with EBV and an increased rate of cervical node metastases. However, most patients, especially younger ones, have a good prognosis.
Medical subject headings
- Carcinoma, Large Cell
- Carcinoma, Squamous Cell
- Epstein-Barr Virus Infections
- Parotid Neoplasms